RecruitingPhase 1NCT06465069
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Sponsor: Eli Lilly and Company
Grand Rapids, MI · +22 more sites
Breast Cancer clinical trials in Grand Rapids, MI
28 recruiting breast cancer studies with a site in Grand Rapids, MI.
RecruitingPhase 3NCT06841354
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
Sponsor: Merck Sharp & Dohme LLC
Grand Rapids, MI · +38 more sites
RecruitingPhase 1 / Phase 2NCT05579366
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Sponsor: Genmab
Detroit, MI · Grand Rapids, MI · +35 more sites
RecruitingPhase 1NCT07114601
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
Sponsor: Eli Lilly and Company
Detroit, MI · Grand Rapids, MI · +14 more sites
RecruitingPhase 3NCT06790693
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
Sponsor: Hoffmann-La Roche
Detroit, MI · Grand Rapids, MI · +60 more sites
RecruitingPhase 1NCT06840886
A Study of PHST001 in Advanced Solid Tumors
Sponsor: Pheast Therapeutics
Ann Arbor, MI · Grand Rapids, MI · +18 more sites
RecruitingPhase 1NCT07454642
AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors
Sponsor: Avacta Life Sciences Ltd
Grand Rapids, MI · +6 more sites
RecruitingPhase 1NCT06270706
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
Sponsor: Pliant Therapeutics, Inc.
Grand Rapids, MI · +15 more sites
RecruitingPhase 1 / Phase 2NCT07189871
177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
Sponsor: Radiopharm Theranostics, Ltd
Grand Rapids, MI · +4 more sites
RecruitingPhase 3NCT05646862
A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy
Sponsor: Hoffmann-La Roche
Detroit, MI · Grand Rapids, MI · +37 more sites
RecruitingNot applicableNCT07214532
Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
Sponsor: Natera, Inc.
Detroit, MI · Grand Rapids, MI · Traverse City, MI · +46 more sites
RecruitingPhase 1 / Phase 2NCT07488676
A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors
Sponsor: Astellas Pharma Global Development, Inc.
Detroit, MI · Grand Rapids, MI · +16 more sites
RecruitingPhase 1NCT07020117
A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors
Sponsor: Aktis Oncology, Inc.
Grand Rapids, MI · +13 more sites
RecruitingPhase 1 / Phase 2NCT05898399
Study of ART6043 in Advanced/Metastatic Solid Tumors Patients (POLKA)
Sponsor: Artios Pharma Ltd
Grand Rapids, MI · +6 more sites
RecruitingPhase 3NCT06492616
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
Sponsor: Stemline Therapeutics, Inc.
Grand Rapids, MI · +175 more sites
RecruitingPhase not listedNCT05059444
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
Sponsor: Guardant Health, Inc.
Grand Rapids, MI · +32 more sites
RecruitingPhase 3NCT05879926
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Sponsor: NRG Oncology
Alma, MI · Alpena, MI · Ann Arbor, MI · +1223 more sites
RecruitingPhase 1NCT06242470
A Study of MGC026 in Participants With Advanced Solid Tumors
Sponsor: MacroGenics
Grand Rapids, MI · +6 more sites
RecruitingPhase 3NCT05812807
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
Sponsor: Alliance for Clinical Trials in Oncology
Ann Arbor, MI · Battle Creek, MI · +825 more sites
RecruitingPhase 3NCT06748222
E-Mindfulness Approaches for Living After Breast Cancer
Sponsor: NRG Oncology
Alma, MI · Alpena, MI · Ann Arbor, MI · +378 more sites
RecruitingPhase 1NCT06562192
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
Sponsor: Novartis Pharmaceuticals
Grand Rapids, MI · +8 more sites
RecruitingPhase 1NCT07318805
A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors
Sponsor: Pfizer
Grand Rapids, MI · +12 more sites
RecruitingPhase 1 / Phase 2NCT05768139
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
Sponsor: Eli Lilly and Company
Detroit, MI · Grand Rapids, MI · +26 more sites
RecruitingPhase 3NCT05696626
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
Sponsor: LeonaBio
Grand Rapids, MI · +35 more sites
RecruitingPhase 3NCT04852887
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
Sponsor: NRG Oncology
Ann Arbor, MI · Battle Creek, MI · +809 more sites
RecruitingPhase 1 / Phase 2NCT06943521
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
Sponsor: Tanabe Pharma America, Inc.
Grand Rapids, MI · +3 more sites
RecruitingPhase 3NCT05929768
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer
Sponsor: SWOG Cancer Research Network
Adrian, MI · Alma, MI · Alpena, MI · +952 more sites
Not yet recruitingEarly Phase 1NCT07781852
Evaluation of the Distribution of 64Cu/68Ga Labeled CM500 in Healthy Volunteers and Patients With Cancer
Sponsor: Lumina Pharmaceuticals Inc
Grand Rapids, MI · +2 more sites
Listings come from ClinicalTrials.gov and are provided for information only. Always confirm eligibility with the study team and talk with your doctor before making decisions about your care.